Wednesday, March 14, 2012 3:34:09 AM
Have to say that the 4Q Financials are REAL BAD.. Only $117K in Sales for the Diagnostic Kits were Received..
Good thing that they closed on all those deals.. 1Q should be a WHOLE lot Better.. Especially if they recognize the $4M Upfront..!
A whole lot of Information to Digest.. Seems like the Known Catalysts have been pushed back on the timeline.. Also seems like we have many Unknown coming..
Responding to your concern GRNI.. In regards to PreVonco.. The 10K does say that they will not commence the PHASE III without a Partner.. Same thing for Femprox.. But.. I would not be so fast to check this off as a NEGATIVE.. Clinical Trials are Expensive and burn through Cash Quick..! Especially a Phase III because of its SIZE..!
As far as Femprox.. Q2 will tell the tale.. ( Hopefully ).. If Health Canada & EMA deem the info from the Clinical Trials enough to file for approval in their Respective territories without the Need of additional trials.. That would be a HUGE Catalyst in my Opinion..!
I have to disagree with you CasinoKid.. You seem to think that the Institutions that came onboard will SELL everything they bought because of the 4Q Sales and the pushback on the known catalysts.. These guys bought at a Higher Price than Current Levels.. The Value in Apricus is Ahead of us.. Not Behind us..!
You also seem to imply that Apricus will need to file for an additional $100 M Shelf..? Guess you missed the part that says that they have enough cash to sustian operations until MID 2014..!
I just took another look at your thread. CasinoKID.. I just realized that you are talking about Retail Investors selling..
( I was going to erase my paragraph where I had my response to your thread, but decided to keep it and add this one )..
Who knows.. You might be right about some Retail Investors Selling.. Only because many are TRADERS.. I still think the PPS will not go under $3..! Short Interest is too BIG..
Time will tell..!
Recent SEEL News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 01:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2024 10:07:04 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/26/2024 08:15:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2024 08:10:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2024 12:53:01 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/25/2024 10:09:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2024 08:05:35 PM
- Biotech Soars On Material Transfer Agreement • AllPennyStocks.com • 09/24/2024 07:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 01:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/26/2024 04:15:16 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/20/2024 08:01:49 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/16/2024 08:02:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/09/2024 08:02:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:06:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 08:01:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:05:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 01:15:52 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/14/2024 08:06:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:05:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:01:36 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2024 08:16:07 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM